MedPath

MEDIMMUNE, LLC

MEDIMMUNE, LLC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

152

Active:142
Completed:6

Trial Phases

4 Phases

Phase 1:122
Phase 2:5
Phase 3:2
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (131 trials with phase data)• Click on a phase to view related trials

Phase 1
122 (93.1%)
Phase 2
5 (3.8%)
Phase 3
2 (1.5%)
Not Applicable
1 (0.8%)
phase_2_3
1 (0.8%)
No trials found

News

NIH Study: Single Dose of MEDI8852 Antibody Shows Complete Protection Against H5N1 Avian Flu in Primates

A groundbreaking NIH study demonstrates that a single dose of MEDI8852, a broadly neutralizing antibody developed by MedImmune/AstraZeneca, provides complete protection against H5N1 avian influenza in macaques.

Aridis Pharmaceuticals Announces Asset Sale and Investment Proposal for Key Pipeline Candidates

• Aridis Pharmaceuticals has executed an agreement to sell AR-501, a therapeutic for chronic bacterial lung infections in cystic fibrosis, for $6.5 million plus royalties. • The company is in discussions for an investment to fund the final Phase 3 study of AR-301, an adjunctive treatment for Ventilator Associated Pneumonia (VAP). • A licensing dispute with MedImmune for AR-320, a VAP prevention candidate, remains unresolved, leading to the likely discontinuation of its Phase 3 trial.

RSV Therapeutic Pipeline Shows Promise with Novel Therapies and Clinical Advancements

• Over 50 companies are actively developing more than 50 therapeutic options for Respiratory Syncytial Virus (RSV) treatment, indicating a robust pipeline. • GSK's Arexvy vaccine demonstrated encouraging Phase III results, preventing lower respiratory tract disease (LRTD) in older adults across three RSV seasons. • Merck's clesrovimab showed positive topline results in a Phase IIb/III trial as a preventive treatment for RSV in infants, highlighting potential for vulnerable populations.

FDA Approves First Self-Administered Flu Vaccine, FluMist, for At-Home Use

• The FDA has approved FluMist, a nasal spray flu vaccine, for self-administration, marking the first flu vaccine that can be administered at home. • FluMist is approved for individuals aged 2 to 49 and will be available through an online pharmacy with a prescription, starting next flu season. • The approval is based on studies showing that adults can safely and effectively administer the vaccine themselves or to children with proper instructions. • This new option aims to improve convenience, flexibility, and accessibility to seasonal influenza vaccination, potentially increasing vaccination rates.

Sanofi Pivots R&D Strategy, Discontinues Diabetes Research to Focus on Novel Therapeutics

• Sanofi announces major strategic shift, discontinuing diabetes and cardiovascular R&D while prioritizing six potentially transformative therapies and its successful Dupixent franchise. • The company's pipeline now features promising candidates including fitusiran for hemophilia, venglustat for rare diseases, and novel treatments for breast cancer and multiple sclerosis. • Strategic realignment expected to generate €2 billion in cost savings, enabling increased investment in pipeline development and wider profit margins.

Oncolytic Viruses Gain Momentum in Cancer Treatment Following Merck's $394M Viralytics Acquisition

Merck & Co's $394 million acquisition of Viralytics signals growing interest in oncolytic viruses as potential enhancers for cancer immunotherapy treatments.

AstraZeneca Expands Immuno-Oncology Portfolio with Three Strategic Partnerships

• AstraZeneca secures rights to Inovio's INO-3112, a DNA vaccine targeting HPV-related cancers, in a deal worth up to $727.5 million, planning combination studies with durvalumab. • MedImmune partners with Heptares on adenosine A2A receptor antagonist HTL-2071 for $510 million, aiming to enhance T-cell anti-cancer activity. • A collaboration with Mirati Therapeutics will explore combining durvalumab with HDAC inhibitor mocetinostat in non-small cell lung cancer trials starting next year.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.